当前位置：
X-MOL 学术
›
Jpn. J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
Japanese Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2021-08-04 , DOI: 10.1093/jjco/hyab114 Yoshihiko Tomita 1 , Go Kimura 2 , Satoshi Fukasawa 3 , Kazuyuki Numakura 4 , Yutaka Sugiyama 5 , Kazutoshi Yamana 1 , Sei Naito 6 , Hirokazu Kaneko 7 , Yohei Tajima 8 , Mototsugu Oya 9
Japanese Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2021-08-04 , DOI: 10.1093/jjco/hyab114 Yoshihiko Tomita 1 , Go Kimura 2 , Satoshi Fukasawa 3 , Kazuyuki Numakura 4 , Yutaka Sugiyama 5 , Kazutoshi Yamana 1 , Sei Naito 6 , Hirokazu Kaneko 7 , Yohei Tajima 8 , Mototsugu Oya 9
Affiliation
We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O.
中文翻译：
AFTER IO 研究的亚组分析：日本转移性肾细胞癌患者免疫肿瘤治疗后后续分子靶向治疗的有效性和安全性的回顾性研究
我们对 AFTER IO 研究进行了亚组分析，以阐明治疗失败时间 (TTF) 和既往免疫肿瘤学 (IO) 治疗以及分子靶向治疗 (TT) 方案与 TT 治疗结果之间的关联。 IO。
更新日期：2021-08-04
中文翻译：
AFTER IO 研究的亚组分析：日本转移性肾细胞癌患者免疫肿瘤治疗后后续分子靶向治疗的有效性和安全性的回顾性研究
我们对 AFTER IO 研究进行了亚组分析，以阐明治疗失败时间 (TTF) 和既往免疫肿瘤学 (IO) 治疗以及分子靶向治疗 (TT) 方案与 TT 治疗结果之间的关联。 IO。
京公网安备 11010802027423号